Board of Directors

David Allen
Mr. Allan has been Chief Executive Officer of the Company since April 1998 and Chairman of the board of directors of the Company since 1994. In addition, Mr. Allan is a Director of Synthemed Inc. (medical devices) USA and DiaMedica Inc. (diabetes therapeutics) Canada.
www.ymbiosciences.com

Matt Buist
LSO Vice-Chair
Matt has more than 30 years of business experience in Canada's medical and biotechnology sectors.
City of Toronto, Office of Economic Dev.

Paul Dick

Denis Ferkany
Denis brings 30 years experience in senior management, business and product development, and strategic alliances in both private industry and public-private partnerships to the ICAV management team. ICAV is a not-for-profit drug development organization dedicated to the discovery and development of anti-viral therapies for neglected and emerging diseases.
ICAV

Anthony J. Giovinazzo
Anthony J. Giovinazzo, M.B.A.; C.Dir.; has 31 years of experience in international investment and operating management, with an emphasis in strategy, mergers and acquisitions, financial management and business development. His industry experience includes, biotechnology, investment banking, mining and manufacturing .
Cervelo Pharmaceuticals Ltd.

 

Jeff Graham
Secretary to Board
Jeffrey Graham is one of Canada’s leading biotech and pharmaceutical regulatory counsel.  He is a partner in the Toronto office of Borden Ladner.
www.blg.com

Rob Hamilton
Rob Hamilton is the President of Hamilton & Company, a strategic healthcare consulting firm located in Burlington, Ontario.
Hamilton & Company

Dr. Raphael (Rafi) Hofstein
Dr. Hofstein joined MaRS Innovation as President and CEO in June 2009.
www.marsinnovation.com

John Kelly
LSO Vice-Chair
Dr. John Kelly is the vice-president of innovation and commercialization for the Ontario Fruit & Vegetable Growers’ Association.
Ontario Fruit & Vegetable Growers’ Association

Jason Locklin
LSO Board Chair
Jason Locklin, Director, Government, Public & Community Relations, Bombardier Aerospace

Lorne Meikle (Board Chair and CEO)
Lorne Meikle is a Director and Past President of LSO and has been the CEO of ten companies in the biotechnology area, both in the public arena and private industry. Lorne is currently the President and Chief Executive Officer of Management Dynamics Ltd., a private company, that provides management services and one that is developing technologies in the biotechnology and water resource areas.

Ian McBeath
Ian McBeath is currently General Manager, Quintiles Commercial, Canada, charged with establishing and building Quintiles’ business in Canada. 

Graeme McRae
Graeme McRae is Chairman, President & CEO of Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company based in Belleville, Ontario, Canada that discovers, develops, manufactures, and commercializes products for both human and veterinary markets around the world.
www.bioniche.com

Allan O'Dette
Allan took on the responsibility of President & CEO of the Ontario Chamber of Commerce on February 1, 2012.
Prior to joining the OCC Allan served as the Director of External Relations (Ontario), and National Private Markets for GlaxoSmithKline Canada Inc.
Ontario Chamber of Commerce

Dale E. Patterson
Dale E. Patterson is the Vice President, External Relations for Genome Canada, having also served as the interim CEO during a transition period, and is on the Board of Directors of each of the 6 regional Genome Centres across Canada.

Dr. Gregory Penner
Dr. Penner brings a wealth of public and private sector research and research management experience to his current leadership position as President and CEO with NeoVentures Biotechnology Inc.
www.neoventures.ca

Mario Piccinin
Treasurer to LSO
Mario Piccinin, a Partner in Ernst & Young LLP’s Toronto North office, has over 20 years of experience providing audit and business advisory services to growth oriented public and private companies.
www.ca.ey.com
 

Mark Smithyes
Mark Smithyes directs Health Policy in Ontario for Novartis and has done so for almost four years.  In this capacity, Mark leads Novartis’ interactions and partnerships with the government, economic stakeholders and patient groups in the province of Ontario.
www.novartis.ca/

 

Jean Szkotnicki
Jean Szkotnicki is President of the Canadian Animal Health Institute (CAHI), a trade association representing companies that develop and manufacture pharmaceuticals, biologicals, feed additives and pesticides for use on animals.
www.cahi-icsa.ca

Peter Van der Velden
Peter joined Lumira Capital as President and CEO in 2005 to lead the generational change from the Company’s founding managers, facilitate the restructuring of the legacy operations of the business and position Lumira as the leading life science investor domiciled in Canada.  Today Peter continues to oversee the overall business operations of the firm while working closely with the senior management team to set and implement strategic direction.
www.lumiracapital.com



Bernard West
Bernard  is currently; Chair of the Board of Ontario BioAuto Council, Co-Chair of the Sustainable Chemistry Alliance], Co-Chair of the Canadian Green Chemistry and Engineering Network, and Chair of the Advisory Board of the Institute for Chemical Process and Environmental Technologies in the National Research Council of Canada.
www.suschemalliance.ca

Russell Williams
Russell Williams is a passionate advocate for innovation in health care and in economic
development. Since joining Rx&D in March 2004, Mr. Williams has promoted policies that improve patient outcomes by expanding patient choice and access to new medicines and vaccines.
www.canadapharma.org